
    
      This is a double blind, randomized, active controlled, phase 3 study. Subjects will be
      randomly assigned to one of the two treatment groups (CJ-12420 100 mg or esomeprazole 40 mg).

      All subjects will be asked to take two tablets at the same time each day throughout the
      study, and also all subjects will be asked to record daytime and nighttime symptom in a
      subject diary on a daily basis.
    
  